Effect of Fetal Aortic Valvuloplasty on Outcomes
Condition(s) studied
Investigational drug(s) / intervention(s)
Fetal aortic balloon dilatation: Fetal valvuloplasty will be performed as described in Arzt W, Wertaschnigg D, Veit I, Klement F, Gitter R, Tulzer G. Intrauterine aortic valvuloplasty in fetuses with critical aortic stenosis: experience and results of 24 procedures. Ultrasound Obstet Gynecol. 2011;37:689-695. with minor variations between centers involved. Technical success is defined as improved forward flow and/or new aortic regurgitation.
Study summary
In one of the most severe congenital heart defects, hypoplastic left heart syndrome (HLHS), the left ventricle is underdeveloped and the prognosis is worse than in most other heart defects. The underdevelopment can occur gradually during fetal growth caused by a narrowing of the aortic valve. At some international centers, such fetuses are treated with a balloon dilation of the narrowed valve, but there is no scientifically sound evidence that this treatment is effective.
The aim of this study is: 1/ to evaluate whether balloon dilation during the fetal period of a narrowed aortic valve can reduce the risk of the left ventricle becoming underdeveloped and the baby being born with a so-called univentricular heart (HLHS); 2/ to investigate whether such treatment improves the prognosis for this group of children with a very complex and severe heart defect and 3/ to also describe side effects and risks in fetuses and mothers of the fetal procedure.
Eligibility
Primary outcome measure(s)
- Transplantation-free survival — Follow-up from study inclusion during fetal life until 2 years postnatal age
Transplantation-free survival from fetal diagnosis to 2 years postnatal age with a biventricular circulation without pulmonary hypertension at that time. Absence of pulmonary hypertension is defined as a TR max velocity ≤ 2.8 m/s with no other echocardiographic signs of pulmonary hypertension and/or catheter data showing a mean pulmonary arterial pressure \<25 mmHg.
Trial sites (13)
| Facility | City | Region | Status |
|---|---|---|---|
| Fetal Cardiovascular Program, University of California San Francisco | San Francisco | California | Recruiting |
| Congenital Heart Collaborative, Nationwide Children's Hospital | Columbus | Ohio | Recruiting |
| Kinderherzzentrum Linz | Linz | Austria | Recruiting |
| The Hospital for Sick Children Toronto | Toronto | Canada | Recruiting |
| Department of Paediatric Cardiology, Helsinki University Children's Hospital | Helsinki | Finland | Recruiting |
| Pediatric Cardiology - University Hospital Bonn | Bonn | Germany | Recruiting |
| Department of Pediatric and Congenital Cardiology, University of Heidelberg | Heidelberg | Germany | Recruiting |
| University hospital Technical university, mother- and-child center | Munich | Germany | Recruiting |
| Department of Perinatal Cardiology and Congenital Anomalies, Centre of Postgraduate Medical Education. | Warsaw | Poland | Recruiting |
| Fetal Medicine Unit, Dept. Obstetrics & Gynecology University Hospital 12 de Octubre | Madrid | Spain | Recruiting |
| Department of Pediatric Cardiology, Skane University Hospital | Lund | Sweden | Recruiting |
| Department of pediatric cardiology, Karolinska Institute | Stockholm | Sweden | Recruiting |
| Department of Pediatrics, Umeå University Hospital | Umeå | Sweden | Recruiting |
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05386173 on ClinicalTrials.gov ↗ ← All trials in Poland